225 related articles for article (PubMed ID: 9423721)
1. A novel protamine variant reversal of heparin anticoagulation in human blood in vitro.
Hulin MS; Wakefield TW; Andrews PC; Wrobleski SK; Stoneham MD; Doyle AR; Zelenock GB; Jacobs LA; Shanley CJ; TenCate VM; Stanley JC
J Vasc Surg; 1997 Dec; 26(6):1043-8. PubMed ID: 9423721
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the hemodynamic and hematologic toxicity of a protamine variant after reversal of low-molecular-weight heparin anticoagulation in a canine model.
Hulin MS; Wakefield TW; Andrews PC; Wrobleski SK; Kadell AM; Downing LJ; Stanley JC
Lab Anim Sci; 1997 Apr; 47(2):153-60. PubMed ID: 9150494
[TBL] [Abstract][Full Text] [Related]
3. A [+18RGD] protamine variant for nontoxic and effective reversal of conventional heparin and low-molecular-weight heparin anticoagulation.
Wakefield TW; Andrews PC; Wrobleski SK; Kadell AM; Tejwani S; Hulin MS; Stanley JC
J Surg Res; 1996 Jun; 63(1):280-6. PubMed ID: 8661211
[TBL] [Abstract][Full Text] [Related]
4. Effective and less toxic reversal of low-molecular weight heparin anticoagulation by a designer variant of protamine.
Wakefield TW; Andrews PC; Wrobleski SK; Kadell AM; Schmidt R; Tejwani S; Stanley JC
J Vasc Surg; 1995 May; 21(5):839-49; discussion 849-50. PubMed ID: 7769743
[TBL] [Abstract][Full Text] [Related]
5. Anticoagulation with heparin during cardiac catheterization and its reversal by protamine.
Dehmer GJ; Haagen D; Malloy CR; Schmitz JM
Cathet Cardiovasc Diagn; 1987; 13(1):16-21. PubMed ID: 3815512
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and toxicity of differently charged polycationic protamine-like peptides for heparin anticoagulation reversal.
DeLucia A; Wakefield TW; Andrews PC; Nichol BJ; Kadell AM; Wrobleski SK; Downing LJ; Stanley JC
J Vasc Surg; 1993 Jul; 18(1):49-58; discussion 58-60. PubMed ID: 8326659
[TBL] [Abstract][Full Text] [Related]
7. Neutralase reverses the anti-coagulant but not the anti-thrombotic activity of heparin in a rabbit model of venous thrombosis.
Silver PJ; Broughton R; Bouthillier J; Quinn TA; Wallace AM; Weishaar RE
Thromb Res; 1998 Aug; 91(3):143-50. PubMed ID: 9733158
[TBL] [Abstract][Full Text] [Related]
8. Anticoagulant effects of protamine sulfate in a canine model.
Kresowik TF; Wakefield TW; Fessler RD; Stanley JC
J Surg Res; 1988 Jul; 45(1):8-14. PubMed ID: 3392995
[TBL] [Abstract][Full Text] [Related]
9. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass.
Mochizuki T; Olson PJ; Szlam F; Ramsay JG; Levy JH
Anesth Analg; 1998 Oct; 87(4):781-5. PubMed ID: 9768770
[TBL] [Abstract][Full Text] [Related]
10. Low molecular weight protamine as nontoxic heparin/low molecular weight heparin antidote (III): preliminary in vivo evaluation of efficacy and toxicity using a canine model.
Lee LM; Chang LC; Wrobleski S; Wakefield TW; Yang VC
AAPS PharmSci; 2001; 3(3):E19. PubMed ID: 11741270
[TBL] [Abstract][Full Text] [Related]
11. Platelet factor 4 efficiently reverses heparin anticoagulation in the rat without adverse effects of heparin-protamine complexes.
Cook JJ; Niewiarowski S; Yan Z; Schaffer L; Lu W; Stewart GJ; Mosser DM; Myers JA; Maione TE
Circulation; 1992 Mar; 85(3):1102-9. PubMed ID: 1537108
[TBL] [Abstract][Full Text] [Related]
12. Heparin neutralization by recombinant platelet factor 4 and protamine.
Levy JH; Cormack JG; Morales A
Anesth Analg; 1995 Jul; 81(1):35-7. PubMed ID: 7598278
[TBL] [Abstract][Full Text] [Related]
13. Neutralization of low molecular weight heparin by polybrene prevents thromboxane release and severe pulmonary hypertension in awake sheep.
Montalescot G; Zapol WM; Carvalho A; Robinson DR; Torres A; Lowenstein E
Circulation; 1990 Nov; 82(5):1754-64. PubMed ID: 2171807
[TBL] [Abstract][Full Text] [Related]
14. Protamine pretreatment attenuation of hemodynamic and hematologic effects of heparin-protamine interaction. A prospective randomized study in human beings undergoing aortic reconstructive surgery.
Wakefield TW; Hantler CB; Lindblad B; Whitehouse WM; Stanley JC
J Vasc Surg; 1986 Jun; 3(6):885-9. PubMed ID: 3712636
[TBL] [Abstract][Full Text] [Related]
15. Andexanet Alfa, the Possible Alternative to Protamine for Reversal of Unfractionated Heparin.
Maneno JN; Ness GL
Ann Pharmacother; 2021 Feb; 55(2):261-264. PubMed ID: 32667214
[TBL] [Abstract][Full Text] [Related]
16. Partial reversal of low molecular weight heparin (PK 10169) anti-Xa activity by protamine sulfate: in vitro and in vivo study during cardiac surgery with extracorporeal circulation.
Massonnet-Castel S; Pelissier E; Bara L; Terrier E; Abry B; Guibourt P; Swanson J; Jaulmes B; Carpentier A; Samama M
Haemostasis; 1986; 16(2):139-46. PubMed ID: 3710291
[TBL] [Abstract][Full Text] [Related]
17. PEG-modified protamine with improved pharmacological/pharmaceutical properties as a potential protamine substitute: synthesis and in vitro evaluation.
Chang LC; Lee HF; Chung MJ; Yang VC
Bioconjug Chem; 2005; 16(1):147-55. PubMed ID: 15656586
[TBL] [Abstract][Full Text] [Related]
18. A case series of recombinant platelet factor 4 for heparin reversal after cardiopulmonary bypass.
Demma L; Levy JH
Anesth Analg; 2012 Dec; 115(6):1273-8. PubMed ID: 22859690
[TBL] [Abstract][Full Text] [Related]
19. Dextran sulfate included in factor Xa assay reagent overestimates heparin activity in patients after heparin reversal by protamine.
Mouton C; Calderon J; Janvier G; Vergnes MC
Thromb Res; 2003; 111(4-5):273-9. PubMed ID: 14693175
[TBL] [Abstract][Full Text] [Related]
20. Effect of high or low protamine dosing on postoperative bleeding following heparin anticoagulation in cardiac surgery. A randomised clinical trial.
Meesters MI; Veerhoek D; de Lange F; de Vries JW; de Jong JR; Romijn JW; Kelchtermans H; Huskens D; van der Steeg R; Thomas PW; Burtman DT; van Barneveld LJ; Vonk AB; Boer C
Thromb Haemost; 2016 Aug; 116(2):251-61. PubMed ID: 27277211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
